Pharmacy closures appear to impact cardiovascular medication adherence among older patients, according to findings from a retrospective cohort study published in JAMA Network Open.

To examine this association, the study authors analyzed prescription claims for patients ≥50 years old using statins, β-blockers, and oral anticoagulants between January 2011 and December 2016. “The differential association of pharmacy closure was examined as a function of baseline adherence, pharmacy, and individual characteristics,” explained the authors. The main outcome measure of the study was the difference in monthly adherence during 12-month baseline and follow-up periods among patients whose pharmacy closed (closure cohort) and those whose pharmacy did not (control cohort).

Related Articles

Results showed that among the 3,089,803 patients who filled ≥1 statin prescription during the study period, 92,287 patients (3%) filled it at a pharmacy that eventually closed. While monthly adherence was found to be similar among both cohorts before the pharmacy closure, a significant decline in statin adherence was noted in the closure cohort immediately after pharmacy closure in the first 3 months (absolute change: −5.90%; 95% CI, −6.12% to −5.69%) and persisted over 12 months. “A similar decline in adherence was observed when examining cohorts using β-blockers (−5.71%; 95% CI, −5.96% to −5.46%) or oral anticoagulants (−5.63%; 95% CI, −6.24% to −5.01%),” the authors reported.

Continue Reading

In addition, the difference in adherence was found to be greater when looking at certain subgroups in the closure cohort such as patients who utilized independent pharmacies (−7.89%; 95% CI, −8.32% to −7.47%), as well as those living in areas with fewer pharmacies (−7.98%; 95% CI, −8.50% to −7.47%).

Based on their findings, the authors concluded that pharmacy closures do have a significant impact on medication adherence in older patients. “Our findings underscore the substantial influence of system-level factors beyond the high cost of prescription drugs on medication nonadherence, especially among patients at highest risk.”

For more information visit

This article originally appeared on MPR